

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 731064552 US  
Express Mail Label NumberSEPTEMBER 21, 2005  
Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

JEFFREY MCKENNA

INTERNATIONAL APPLICATION NO: PCT/EP03/08720

FILED: 7 FEBRUARY 2005

U.S. APPLICATION NO: 10/523,870

35 USC §371 DATE: Not Yet Known

FOR: ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF  
ALDOSTERONE MEDIATED CONDITIONS**Mail Stop: Amendment**Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits. Under 37 C.F.R. §1.97(b)(3), no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


The listed references were cited in the International Search Report. Since these references are of record in the instant PCT application PCT/EP03/08720, copies are not enclosed herewith.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3346

  
Cynthia Zhang  
Attorney for Applicant  
Reg. No. 53,827

Date: September 21, 2005

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
PC/4-32611A  
APPLICATION NO.  
10/523,870  
APPLICANT  
Jeffrey Mc Kenna  
FILING DATE

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,617,307	10/14/86	Browne	514	300	06/20/84
	AB	4,889,861	12/26/89	Browne	514	300	11/13/87
	AC	5,529,992	06/25/96	Weber	514	175	12/02/93
	AD	6,150,347	11/21/00	Weber	514	175	03/29/99
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 97/00257	01/03/97	WIPO [English Abstract 1997-077476/199707]			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Janin et al., "Imidazo[1,5-g][1,4]diazepines, TIBO Analogues Lacking the Phenyl Ring: Synthesis and Evaluation as Anti-HIV Agents", <i>Tetrahedron</i> , Vol. 52, No. 48, pp. 15157-15170 (1996).
	AS	Yamauchi and Masui, "Synthesis of 6,7,8,9-tetrahydro-5H-imidazo[1,5-a][1,4]diazepines", <i>Chem Industry</i> , No. 1, pp. 31-32 (1976).
	AT	Yamauchi and Masui, "Reactivity of 2,4(5)-Dialkylimidazoles. Synthesis of 6,7,8,9-Tetrahydro-5H-imidazo[1,5-a][1,4]diazepine Derivatives", <i>Chem Pharm Bull</i> , Vol. 24, No. 7, pp. 1480-1484 (1976).

EXAMINER /Jeffrey Murray/

DATE CONSIDERED 03/31/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./